The global diabetic macular edema market size is expected to reach a valuation of US$ 3.7 Bn by the end of 2022, and further expand at a CAGR of 1.2% from 2022 to 2032. The market is projected to reach a valuation of ~US$ 4.2 Bn by the end of 2032. Anti-VEGF products are leading the market in terms of drugs and they held a share of about 95.5%in 2021 in the global market. Below-mentioned factors are expected to play a pivotal role in furthering market growth
An Uptake of Intravitreal Implants by Patients to Drive Growth of the Market in North America
North America will remain dominant in the global diabetic macular edema market. An uptake of intravitreal implants by new as well as existing patients, who do not show any improvement post-treatment with intravitreal injections, is expected to sustain growth of the market in this region.
Although control of diabetes is a health priority in developed North American countries, such as the U.S., less attention is given to DME management, with diabetes-related caregivers tending to focus on treatment of diabetic complications. A major reason behind this is lack of effective treatment for DME in North America. In addition, an error exists between industry sponsored and independently run clinical trials. Most of the independent clinical trials for DME treatment lack long-term results pertaining to safety and efficacy of new combination therapies for DME. These factors are likely to inhibit growth of the market in North America.
Diabetic Macular Edema Market in Western Europe to Register the Highest CAGR through 2027
The diabetic macular edema market in Western Europe is expected to register a comparatively higher CAGR than other region segments through 2027. Pharmaceutical companies in this region are making substantial investments in research and development, new technologies, and infrastructure in order to capture a market share in the surging burden of eye diseases. This is expected to retain growth of the market in Western Europe.
However, patients in Western Europe resist the intake of intravitreal injections of anti-VEGF drugs, which leads to an instant increase in intraocular pressure causing severe pain in the head or eyes. This a major factor impeding growth of the diabetic macular edema market in Western Europe.
Request Sample Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-2697
Anti-VEGF will Remain Preferred Product in the Global Diabetic Macular Edema Market
Anti-VEGF will remain preferred product in the market, with sales estimated to expand at 1% CAGR through 2027. Eylea will continue to be the most lucrative anti-VEGF drug in the market. However, demand for corticosteroids will remain comparatively lower than anti-VEGF during the forecast period.
By product form, intravitreal injections will continue to be sought-after in the market, with sales poised to surpass US$ 4,000 Mn by 2027-end. Sales of intravitreal implants will register a comparatively higher CAGR than intravitreal injections through 2027.
Hospital pharmacy is estimated to remain the largest distribution channel in the market, as majority of countries across the globe dispense intravitreal injections and implants to outpatients by hospital pharmacies. Retail pharmacy, which mainly provides aliquots of off-label indications such as Avastin prescription, will register a comparatively low CAGR than hospital pharmacy in the market through 2027.
Key market players identified in FMI’s report include Novartis AG, Bayer AG, Allergan Plc., F. Hoffman-La Roche Ltd., Alimera Sciences Inc., Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
Get In Touch With Our Team For 20% Flat Discount:
https://www.futuremarketinsights.com/ask-question/rep-gb-2697
Key Segments Covered In Diabetic Macular Edema Market Report
By Drug:
- Anti-VEGF
- Ranibizumab (Lucentis)
- Aflibercept (Eylea)
- Corticosteroid Therapies
- Dexamethasone (Ozurdex)
- Fluocinolone Acetonide (Iluvien)
- Other Off-label Drugs
By Form:
- Intravitreal Injections
- Intravitreal Implants
By Distribution Channel:
- Hospitals
- Specialty Clinics
- Mail Order Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Ask for Customization:
https://www.futuremarketinsights.com/customization-available/rep-gb-2697
Have a Look at More Valuable Insights of Healthcare
Diabetic Shoes Market Size is expected to reach a valuation of US$ 7.9 Bn in 2022 and is further projected to grow at a robust CAGR of 6.4% during the forecast period between 2022 and 2032
Diabetic Retinopathy Treatment Market Share covering sales outlook, demand forecast & up-to-date key trends
Diabetic Nephropathy Market Demand is expected to influence the demand for global diabetic nephropathy market during the forecast period of 2016-2026
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the market intelligence engine from Future Market Insights. Sign Up for a 7 day free trial!
Contact Us:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
Enquiries: sales@futuremarketinsights.com